Enhancing Treatment Experiences in Castration-Resistant Prostate Cancer: The Nurse's View

STATEMENT OF NEED

Prostate cancer is the most common tumor type affecting men in the United States, with an estimated 174,650 new cases reported each year. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Nonmetastatic CRPC is a highly heterogeneous disease process with a dearth of effective treatment options. Metastatic CRPC is the primary cause of prostate-related mortality, accounting for an estimated 31,620 deaths annually. Median overall survival remains less than 2 years.

TARGET AUDIENCE

Oncology and urology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with castration-resistant prostate cancer (CRPC).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

1.) Identify patient and tumor characteristics that can tailor CRPC treatment plans to individual patients
2.) Distinguish the safety and efficacy profiles of novel therapies for nonmetastatic and metastatic CRPC
3.) Apply strategies to manage adverse events associated with novel therapies for nonmetastatic and metastatic CRPC